Aptose Biosciences (TSE:APS) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Aptose Biosciences is advancing the development of its promising drug tuspetinib as part of a triplet therapy for acute myeloid leukemia (AML), showing strong clinical activity and a unique safety profile. The company has secured a $10 million loan from Hanmi Pharmaceutical to support the clinical development of tuspetinib, with plans for a new co-development collaboration. Tuspetinib has demonstrated potential to address unmet needs in AML treatment by avoiding common toxicities associated with other therapies.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
